Literature DB >> 21212092

Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.

Victor A Gault1, David W Porter, Nigel Irwin, Peter R Flatt.   

Abstract

Glucose-dependent insulinotropic polypeptide (GIP) is a 42 amino acid hormone secreted from intestinal K-cells, which exhibits a number of actions including stimulation of insulin release. A truncated form, GIP(1-30), has recently been demonstrated in intestine and islet α-cells. To evaluate the potential physiological significance of this naturally occurring form of GIP, the present study has examined and compared the bioactivity of enzymatically stabilised forms, [D-Ala²]GIP(1-30) and [D-Ala²]GIP(1-42), in high-fat fed mice. Twice-daily injection of GIP peptides for 42 days had no significant effect on food intake or body weight. However, non-fasting glucose levels were significantly lowered, and insulin levels were elevated in both treatment groups compared to saline controls. The glycaemic response to i.p. glucose was correspondingly improved (P < 0.05) in [D-Ala²]GIP(1-30)- and [D-Ala²]GIP(1-42)-treated mice. Furthermore, glucose-stimulated plasma insulin levels were significantly elevated in both treatment groups compared to control mice. Insulin sensitivity was not significantly different between any of the groups. Similarly, plasma lipid profile, O₂ consumption, CO₂ production, respiratory exchange ratio, and energy expenditure were not altered by 42 days twice-daily treatment with [D-Ala²]GIP(1-30) or [D-Ala²]GIP(1-42). In contrast, ambulatory activity was significantly (P < 0.05) elevated during the light phase in both GIP treatment groups compared to saline controls. The results reveal that sustained GIP receptor activation exerts a spectrum of beneficial metabolic effects in high-fat fed mice. However, no differences were discernable between the biological actions of the enzyme-resistant analogues of the naturally occurring forms, GIP(1-30) and GIP(1-42).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212092     DOI: 10.1530/JOE-10-0419

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  19 in total

Review 1.  Pursuit of a perfect insulin.

Authors:  Alexander N Zaykov; John P Mayer; Richard D DiMarchi
Journal:  Nat Rev Drug Discov       Date:  2016-03-18       Impact factor: 84.694

2.  Pancreatic glucose-dependent insulinotropic polypeptide (GIP) (1-30) expression is upregulated in diabetes and PEGylated GIP(1-30) can suppress the progression of low-dose-STZ-induced hyperglycaemia in mice.

Authors:  Tsuyoshi Yanagimachi; Yukihiro Fujita; Yasutaka Takeda; Jun Honjo; Kuralay K Atageldiyeva; Yumi Takiyama; Atsuko Abiko; Yuichi Makino; Timothy J Kieffer; Masakazu Haneda
Journal:  Diabetologia       Date:  2015-12-22       Impact factor: 10.122

3.  The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection.

Authors:  Peter Lindquist; Lærke Smidt Gasbjerg; Jacek Mokrosinski; Jens Juul Holst; Alexander Sebastian Hauser; Mette Marie Rosenkilde
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-29       Impact factor: 6.055

4.  A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.

Authors:  Aisling M Lynch; Nupur Pathak; Varun Pathak; Finbarr P M O'Harte; Peter R Flatt; Nigel Irwin; Victor A Gault
Journal:  Diabetologia       Date:  2014-06-25       Impact factor: 10.122

5.  A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.

Authors:  Victor A Gault; Vikas K Bhat; Nigel Irwin; Peter R Flatt
Journal:  J Biol Chem       Date:  2013-10-28       Impact factor: 5.157

6.  Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice.

Authors:  N Irwin; I A Montgomery; P R Flatt
Journal:  Diabetologia       Date:  2013-03-06       Impact factor: 10.122

7.  GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis.

Authors:  Su-Jin Kim; Cuilan Nian; Subashini Karunakaran; Susanne M Clee; Carlos M Isales; Christopher H S McIntosh
Journal:  PLoS One       Date:  2012-07-03       Impact factor: 3.240

8.  A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents.

Authors:  K Tatarkiewicz; D M Hargrove; C M Jodka; B R Gedulin; P A Smith; J A Hoyt; A Lwin; L Collins; L Mamedova; O E Levy; L D'Souza; S Janssen; V Srivastava; S S Ghosh; D G Parkes
Journal:  Diabetes Obes Metab       Date:  2013-08-19       Impact factor: 6.577

9.  Role of endogenous GLP-1 and GIP in beta cell compensatory responses to insulin resistance and cellular stress.

Authors:  Srividya Vasu; R Charlotte Moffett; Bernard Thorens; Peter R Flatt
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

10.  N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.

Authors:  L S Hansen; A H Sparre-Ulrich; M Christensen; F K Knop; B Hartmann; J J Holst; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2016-01-30       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.